Martin C., Daly A., Shane-McWhorter L., Shwide-Slavin C., Kushion W.The scope of practice, standards of practice, and standards of professional performance for diabetes educators. Diabetes Educ. 2005;31:487-512.
2.
American Nurses Association and American Association of Diabetes Educators.Scope and Standards of Diabetes Nursing Practice. 2nd ed. Washington, DC: American Nurses Association; 2003.
3.
Kulkarni K., Boucherl JL, Daly A., et al. American Dietetic Association: Standards of practice and standards of professional performance for registered dietitians (generalist, specialty, and advanced) in diabetes care. J Am Diet Assoc. 2005;105:819-824.
4.
Centers for Disease Control and Prevention.National diabetes fact sheet. http://www.cdc.gov/diabetes/pubs/factsheet05.htm . Accessed June 21, 2008.
5.
Duncan GEPrevalence of diabetes and impaired fasting glucose levels among US adolescents: National Health and Nutrition Examination Survey, 1999-2002. Arch Pediatr Adolesc Med. 2006;160:523-528.
6.
American Diabetes Association.Direct and indirect costs of diabetes in the US. 2007. www.diabetes.org/diabetes-statistics/costof-diabetes-in-us.jsp . Accessed June 21, 2008.
7.
Report of the Task Force on the Delivery of Diabetes Self-management Education and Medical Nutrition Therapy. Diabetes Spectrum . 1999;12(1).
8.
Mensing C., Boucher J., Cypress M., et al. National standards for diabetes self-management education. Diabetes Care. 2004; 27(suppl 1):S143-S150.
9.
American Diabetes Association.Standards of medical care in diabetes-2008 . Diabetes Care. 2008;31:S12-S54.
10.
Funnell MM, Brown TL, Childs BP, et al: National standards for diabetes self-management education. Diabetes Care. 2007;30: 1630-1637.
11.
Kiel PJ, McCord ADCollaborative practice agreement for diabetes management [letter] . Am J Health Syst Pharm. 2006;63:209-210.
12.
American Diabetes Association and National Institute of Diabetes, Digestive and Kidney Diseases.The prevention and delay of type 2 diabetes [position statement]. Diabetes Care. 2002;25:742-749.
13.
Pan XR, Li GW, Hu YH, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care. 1997;20:537-544.
14.
Tuomilehto J., Lindstrom J., Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344:1343-1350.
15.
Diabetes Prevention ProgramResearch Group.Reduction in the evidence of type 2 diabetes with life-style intervention or metformin . N Engl J Med. 2002;346:393-403.
16.
Buchanan TA , Xiang AH, Peters RK, et al. Preservation of pancreatic β-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes. 2002;51:2796-2803.
17.
Xiang AH, Peters RK, Kjos SL, et al. The pioglitazone in prevention of diabetes (PIPOD) trial. Diabetes. 2006;55:517-522.
18.
Chiasson JL , Josse RG, Gomis R., et al; for the STOP-NIDDM Trial Research Group.Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet . 2002;359:2072-2077.
19.
DREAM (Diabetes Reduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators.Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial . Lancet. 2006;368:1096-1105.
20.
Diabetes Control and Complications Trial Research Group.The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-986.
21.
UK Prospective Diabetes Study Group.Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-853.
22.
Diabetes Control and Complications Trial /Epidemiology of Diabetes Interventions and Complications Research Group.Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA. 2002;287:2563-2569.
23.
Diabetes Control and Complications Trial /Epidemiology of Diabetes Interventions and Complications Research Group.Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) Study. JAMA. 2003;290:2159-2167.
24.
Martin CL, Albers J., Herman WH, et al; for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group.Neuropathy among the diabetes control and complications trial cohort 8 years after trial completion. Diabetes Care. 2006;29:340-344.
25.
Nathan DM, Cleary PA, Backlund JY, et al; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group.Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353:2643-2653.
26.
Harris MIMedical care for patients with diabetes: epidemiologic aspects. Ann Intern Med. 1996;124(1 pt 2):117-122.
27.
Kroon LA, Coleman LT, Koda-Kimble MAThe management of type 2 diabetes mellitus: a call to action for pharmacists . US Pharm. 1997;(suppl 1):1-18.
28.
US Department of Labor, Bureau of Labor Statistics.Earnings [article online] 2004. http://www.bls.gov/oco/ocos079.htm#earnings.
29.
Choe MH, Mitrovich S., Dubay D., et al. Proactive case management of high-risk patients with type 2 diabetes mellitus by a clinical pharmacist: a randomized controlled trial . Am J Manag Care. 2005;11(4):253-260.
30.
Clifford R. , Davis W., Batty K., Davis TMEEffect of a pharmaceutical care program on vascular risk factors in type 2 diabetes . Diabetes Care . 2005;4:771-776.
31.
Jaber LA, Halapy H., Fernet M., Tummalapalli S., Diwakaran H.Evaluation of a pharmaceutical care model on diabetes management. Ann Pharmacother. 1996;30(3):238-243.
32.
Leal S., Glover J., Herrier R., Felix A.Improving quality of care in diabetes through a comprehensive pharmacist based disease management program. Diabetes Care. 2004;27(12):2983-2984.
33.
Cranor CWOutcomes of the Asheville diabetes project. Pharmacy Times . 1998;(suppl):19-25.
34.
Cranor CW, Christensen DBThe Asheville Project: short-term outcomes of a community pharmacy diabetes care program. J Am Pharm Assoc. 2003 ;43:149-159.
35.
Cranor CW, Christensen DBThe Asheville Project: factors associated with outcomes of a community pharmacy diabetes care program. J Am Pharm Assoc. 2003 ;43:160-172.
36.
Cranor CW, Bunting BA, Christensen DBThe Asheville Project: long-term clinical and economic outcomes of a community pharmacy diabetes care program. J Am Pharm Assoc . 2003;43:173-184.
37.
Coast-Senior EA, Kroner BA, Kelley CI, Trilli LEManagement of patients with type 2 diabetes by pharmacists in primary care clinics. Ann Pharmacother. 1998;32:636-641.
38.
Harris IM, Baker E., Berry TM, et al; for American College of Clinical Pharmacy.Developing a business-practice model for pharmacy services in ambulatory settings. Pharmacotherapy. 2008 ;28:7e-34e.
39.
Gong C., Hasson NK, Lum BLImpact of a diabetes disease management clinic on the total glycosylated hemoglobin of patients with type 2 diabetes mellitus. J Managed Care Pharm. 1999; 5(6):511-515.
40.
Cioffi ST, Caron MF, Kalus JS, Hill P., Buckley TEGlycosylated hemoglobin, cardiovascular, and renal outcomes in a pharmacist-managed clinic. Ann Pharmacother. 2004;38(5):771-775.
41.
Carmichael JM , Alvarez A., Chaput R., DiMaggio J., Magallon H., Mambourg S.Establishment and outcomes of a model primary care pharmacy service system. Am J Health Syst Pharm. 2004; 61(5):472-482.
42.
Felt-Lisk S. , Mays G., Harris L., Lee M., Nyman R., Smieliauskas F.Evaluation of HRSA’s clinical pharmacy demonstration projects. Final report. November 30, 2004. MPR reference no 8928-500. http://www.mathematica-mpr.com/publications/PDFs/evalhrsavol1.pdf . Accessed June 21, 2008.
43.
Shane-McWhorter L., Oderda GMProviding diabetes education and care to underserved patients in a collaborative practice at a Utah community health center. Pharmacotherapy. 2005;25(1):96-109.
44.
Glenn ZM, Simmons ML, West CP, Schmidt AMAdvantages of a pharmacist-led diabetes education program. US Pharm. 2005;11:52-61.
45.
Yanchick JKImplementation of a drug therapy monitoring clinic in a primary-care setting. Am J Health Syst Pharm. 2000;57(suppl 4):S30-S34.
46.
Morello CM, Zadvorny EB, Cording MA, Suemoto RT, Harari A.Development and clinical outcomes of pharmacist-managed diabetes care clinics . Am J Health-Syst Pharm. 2006;63:1325-1331.
47.
Gerber RA, Liu G., McCombs JSImpact of pharmacist consultations provided to patients with diabetes on healthcare costs in a health maintenance organization. Am J Manag Care . 1998;4(7): 991-1000.
48.
McConnell KJ , Humphries TL, Raebel MA, Merenich JAClinical pharmacy specialist implementation of lisinopril therapy in patients with coronary artery disease and diabetes mellitus. Pharmacotherapy. 2003;23(12):1564-1572.
49.
McCord ADClinical impact of a pharmacist-managed diabetes mellitus drug therapy management service. Pharmacotherapy . 2006; 26:248-253.
50.
Nicholas A. , Divine H., Nowak-Rapp M., Roberts KBUniversity and college of pharmacy collaboration to control health plan prescription drug costs. J Am Pharm Assoc. 2007;47:86-92.
51.
Letassy NA, Armor BL, Britton ML, Farmer KCPharmacist-managed diabetes service in a family medicine practice improves patient outcomes. Drug Benefit Trends. 2003 ;15(suppl H):21-32.
52.
Ragucci KR, Fermo JD, Wessell AM, Chumney ECEffectiveness of pharmacist-administered diabetes mellitus education and management services. Pharmacotherapy. 2005;25(12): 1809-1816.
53.
Rothman RL, Malone R., Bryant B., et al. A randomized trial of a primary care-based disease management program to improve cardiovascular risk factors and glycated hemoglobin levels in patients with diabetesAm J Med. 2005;118(3):276-284.
54.
Nowak SN, Singh R., Clarke A., Campbell E., Jaber LAMetabolic control and adherence to American Diabetes Association practice guidelines in a pharmacist-managed diabetes clinic. Diabetes Care. 2002;25(8):1479.
55.
Kiel PJ, McCord ADPharmacist impact on clinical outcomes in a diabetes disease management program via collaborative practice. Ann Pharmacother. 2005;39:1828-1832.
56.
Kelly C., Rodgers PTImplementation and evaluation of a pharmacist managed diabetes service . J Managed Care Pharm. 2000;6(6):488-493.
57.
Stroup J., Kane MP, Busch RS, Bakst G., Hamilton RAThe diabetes home visitation program. Am J Pharm Educ . 2003;67(3):1-8.
58.
Jensen B.One year’s experience. The Lakeshore Diabetes Project: from Asheville to Wisconsin. Journal of the Pharmacy Society of Wisconsin . 2004;November/December:22-23.
59.
Garrett DG, Bluml BMPatient self-management program for diabetes: first year clinical, humanistic, and economic outcomes. J Am Pharm Assoc. 2005 ;45:130-137.
60.
Baran RW, Crumlish K., Patterson H., et al. Improving outcomes of community-dwelling older patients with diabetes through pharmacist counseling. Am J Health Syst Pharm . 1999;56(15):1535-1539.
61.
Hogue VW, Babamoto KS, Jackson TB, Cohen LB, Laitinen DLPooled results of community pharmacy-based diabetes education programs in underserved communities. Diabetes Spectrum. 2003;16(2):129-133.
62.
West D., Blevins MA, Brech D., Stotts F., Gardner S.A multidisciplinary approach in a community pharmacy can improve outcomes for diabetes patients. Diabetes Educ. 2003 ;29(6):962-968.
63.
Nau DP, Blevins JD, Neal SECollaborating with community pharmacists to improve the quality of diabetes care in an IPAmodel HMO. J Manag Care Pharm. 2001;7:292-296.
64.
Nau DP, Ponte CDEffects of a community pharmacist-based diabetes patient management program on intermediate clinical outcome measures. J Manag Care Pharm . 2002;8(1):48-53.
65.
Munroe WP, Kunz K., Dalmady-Israel C., Potter L., Schonfeld WHEconomic evaluation of pharmacist involvement in disease management in a community pharmacy setting. Clin Ther. 1997;19(1): 113-123.
66.
Wubben DP, Vivian EMEffects of pharmacist outpatient interventions on adults with diabetes mellitus: a systematic review. Pharmacotherapy. 2008 ;28:421-436.
